The aim is to evaluate the effects of tofacitinib on secretory dysfunction and immune imbalance in a murine model of Sjögren’s disease.
Utilized a murine model of Sjögren’s disease (SjD) to assess the effects of tofacitinib.
Administered tofacitinib and monitored changes in secretory function and immune cell balances.
Analyzed the influence on Th17 and Treg cells.
Tofacitinib significantly reduced secretory dysfunction in the SjD model.
There was a notable improvement in the balance of Th17 and Treg cells post-treatment.
Increased modulation of inflammation was observed following tofacitinib administration.
Abstract
Tofacitinib potently attenuated secretory dysfunction and inflammation in SjD mice, possibly by modulating Th17/Treg balance, suggesting it may be a therapeutic agent for SjD.
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren’s disease murine model | Synapse